Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Asterias Biotherapeutics announces management change - Form 8-K


Friday, 11 Apr 2014 05:19pm EDT 

Asterias Biotherapeutics Inc:On April 10, Board terminated employment of president and chief executive officer, Thomas Okarma.Also on April 10, board appointed vice president of Technology Integration, Michael D. West, as president and chief executive officer.